Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

https://ift.tt/at0uBEL

Dupixent^® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

from Sanofi - Aventis Groupe https://ift.tt/BL5GdqI
via IFTTT